DBV Technologies

DBV Technologies Equity

The The Equity of DBV Technologies (DBVT) as of Oct 19, 2026 is 168.77 M USD. In the previous year, The Equity was 27.39 M USD — a change of 516.22% (higher).

Equity

168.77 MUSD

YoY

516.22%

Last updated:

In 2025, DBV Technologies's equity was 168.77 M USD, a 516.22% increase from the 27.39 M USD equity in the previous year.

The DBV Technologies Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
191.18 M USD
Jan 1, 2019
222.78 M USD
Jan 1, 2020
236.97 M USD
Jan 1, 2021
114.20 M USD
Jan 1, 2022
224.25 M USD
Jan 1, 2023
161.66 M USD
Jan 1, 2024
27.39 M USD
Jan 1, 2025
168.77 M USD
The DBV Technologies Equity history
YEAREquityYoY
168.77 MUSD+516.22%
27.39 MUSD-83.06%
161.66 MUSD-27.91%
224.25 MUSD+96.36%
114.20 MUSD-51.81%
236.97 MUSD+6.37%
222.78 MUSD+16.53%
191.18 MUSD-9.35%
210.90 MUSD-31.74%
308.95 MUSD-30.28%
443.11 MUSD+110.86%
210.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DBV Technologies Stock analysis

What does DBV Technologies do? DBV Technologies, headquartered in Châtillon, France, is a clinical-stage biopharmaceutical company focused on developing epicutaneous immunotherapy products for food allergies. The company's pipeline includes Viaskin Peanut, which completed Phase 3 trials for peanut allergy treatment, and Viaskin Milk, in Phase 1/2 for cow's milk protein allergy. It also develops the Viaskin technology platform and collaborates with Nestlé Health Science on MAG1C for diagnosing non-IgE mediated CMPA. Listed in 2014, the company employs 125 people and operates in the Health Care sector. DBV Technologies is one of the most popular companies on Eulerpool.

Equity Details

Analyzing DBV Technologies's Equity

DBV Technologies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding DBV Technologies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating DBV Technologies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

DBV Technologies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in DBV Technologies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about DBV Technologies stock

The Equity of DBV Technologies is 168.77 M USD in 2025.

The Equity of DBV Technologies changed from 27.39 M USD to 168.77 M USD, representing a 516.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity DBV Technologies since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's DBV Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DBV Technologies

All Key Metrics — DBV Technologies